Ambient air pollution and lipoprotein-associated phospholipase A2 in survivors of myocardial infarction

Environmental Health Perspectives

Volumn 119, Issue 7, 2011, Pages 921-926

  Brüske, Irene ^a   Hampel, Regina ^a   Baumgärtner, Zita ^b   Rückerl, Regina ^a   Greven, Sonja ^c   Koenig, Wolfgang ^d   Peters, Annette ^a   Schneider, Alexandra ^a  

^a INSTITUTE OF EPIDEMIOLOGY   (Germany)

^b Institut fur Medizinische Informationsverarbeitung   (Germany)

^c UNIVERSITY OF MUNICH   (Germany)

^d UNIVERSITY HOSPITAL ULM   (Germany)

Author keywords

Air pollution; Atherosclerosis; Epidemiology; Inflammation; Lipoprotein associated phospholipase a2; Myocardial infarction; Panel study

Indexed keywords

1 ALKYL 2 ACETYLGLYCEROPHOSPHOCHOLINE ESTERASE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CARBON MONOXIDE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; FIBRIC ACID DERIVATIVE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; NITRIC OXIDE; NITROGEN DIOXIDE; OZONE; SULFUR DIOXIDE;

1 ALKYL 2 ACETYLGLYCEROPHOSPHOCHOLINE ESTERASE BLOOD LEVEL; ADULT; AGED; AIR POLLUTANT; AIR POLLUTION; AMBIENT AIR; ARTICLE; CARDIOVASCULAR RISK; CONCENTRATION (PARAMETERS); DISEASE ASSOCIATION; ENVIRONMENTAL MONITORING; ENZYME BLOOD LEVEL; FEMALE; GERMANY; HEART INFARCTION; HUMAN; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSPECTIVE STUDY; SURVIVOR; SUSPENDED PARTICULATE MATTER;

EID: 79960038616     PISSN: 00916765     EISSN: 15529924     Source Type: Journal    
DOI: 10.1289/ehp.1002681     Document Type: Article

References (30)

1. Aalto P, Hämeri K, Paatero P, Kulmala M, Bellander T, Berglind N, et al. 2005. Aerosol particle number concentration measurements in five European cities using TSI-3022 condensation particle counter over a three-year period during health effects of air pollution on susceptible subpopulations. J Air Waste Manag Assoc 55(8):1064-1076.
2. Akaike H. 1973. Information theory and an extension of the maximum likelihood principle. In: Second International Symposium on Information Theory (Petrov BN, Csaki F, eds). Budapest:Akademiai Kiado, 267-281.
3. Alpert JS, Thygesen K, Antman E, Bassand JP, et al. 2000. Myocardial infarction redefined-a consensus document of the Joint European Society of Cardiology/American College of Cardiology Committee for the Redefinition of Myocardial Infarction. J Am Coll Cardiol 36(3):959-969.
4. Anderson JL. 2008. Lipoprotein-associated phospholipase A(2): an independent predictor of coronary artery disease events in primary and secondary prevention. Am J Cardiol 101(12A):23F-33F.
5. Balsinde J, Balboa MA, Dennis EA. 1998. Functional coupling between secretory phospholipase A2 and cyclooxygenase-2 and its regulation by cytosolic group IV phospholipase A2. Proc Natl Acad Sci U.S.A. 95(14):7951-7956.
6. Beck-Speier I, Dayal N, Karg E, Maier K, Schumann G, Schulz H, et al. 2005. Oxidative stress and lipid mediators induced in alveolar macrophages by ultrafine particles. Free Radic Biol Med 38(8):1080-1092.
7. Brook RD, Rajagopalan S, Pope CA III, Brook JR, Bhatnagar A, Diez-Roux AV, et al. 2010. Particulate matter air pollution and cardiovascular disease: an update to the scientific statement from the American Heart Association. Circulation 121(21):2331-2378.
8. Cyrys J, Pitz M, Heinrich J, Wichmann HE, Peters A. 2008. Spatial and temporal variation of particle number concentration in Augsburg, Germany. Sci Total Environ 401(1-3):168-175.
9. de Hartog JJ. 2003. Effects of fine and ultrafine particles on cardiorespiratory symptoms in elderly subjects with coronary heart disease: the ULTRA study. Am J Epidemiol 157(7):613-623.
10. 2.5 and heart rate variability are modified by particle composition and beta-blocker use in patients with coronary heart disease. Environ Health Perspect 117(1):105-111.
11. Gorelick PB. 2008. Lipoprotein-associated phospholipase A2 and risk of stroke. Am J Cardiol 101(12A):34F-40F.
12. Greven S, Küchenhoff H, Peters A. 2006. Additive mixed models with P-splines. Available: http://www.statuni-muenchen.de/~greven/files/greven_iwsm06.pdf [accessed 30 May 2011].
13. Hill AM, Fleming JA, Kris-Etherton PM 2009. The role of diet and nutritional supplements in preventing and treating cardiovascular disease. Curr Opin Cardiol 24(5):433-441.
14. Iribarren C, Gross MD, Darbinian JA, Jacobs DR, Sidney S, Loria CM. 2005. Association of lipoprotein-associated phospholipase A2 mass and activity with calcified coronary plaque in young adults - the CARDIA study. Arterioscler Thromb Vasc Biol 25(1):216-221.
15. Katsouyanni K, Schwartz J, Spix C, Touloumi G, Zmirou D, Zanobetti A, et al. 1996. Short-term effects of air pollution on health: a European approach using epidemiologic time series data: the APHEA protocol. J Epidemiol Community Health 50(suppl 1):S12-S18.
16. Khuseyinova N, Greven S, Ruckerl R, Trischler G, Loewel H, Peters A, et al. 2008. Variability of serial lipoprotein-associated phospholipase A2 measurements in post-myocardial infarction patients: results from the AIRGENE Study Center Augsburg. Clin Chem 54(1):124-130.
17. Koenig W, Khuseyinova N. 2009. Lipoprotein-associated and secretory phospholipase A2 in cardiovascular disease: the epidemiological evidence. Cardiovasc Drugs Ther 23(1):85-92.
18. Koenig W, Twardella D, Brenner H, Rothenbacher D. 2006. Lipoprotein-associated phospholipase A2 predicts future cardiovascular events in patients with coronary heart disease independently of traditional risk factors, markers of inflammation, renal function, and hemodynamic stress. Arterioscler Thromb Vasc Biol 26(7):1586-1593.
19. Koenig W, Vossen CY, Mallat Z, Brenner H, Benessiano J, Rothenbacher D. 2009. Association between type II secretory phospholipase A2 plasma concentrations and activity and cardiovascular events in patients with coronary heart disease. Eur Heart J 30(22):2742-2748.
20. Lerman A, McConnell J. 2008. Lipoprotein-associated phospholipase A2: a risk marker or a risk factor? Am J Cardiol 101(A12):11F-22F.
21. Lp-PLA(2) Studies Collaboration, Thompson A, Gao P, Orfei L, Watson S, Di Angelantonio E, et al. 2010. Lipoprotein-associated phospholipase A2 and risk of coronary disease, stroke, and mortality: collaborative analysis of 32 prospective studies. Lancet 375(9725):1536-1544.
22. Macphee CH, Moores KE, Boyd HF, Dhanak D, Ife RJ, Leach CA, et al. 1999. Lipoprotein-associated phospholipase A2, platelet-activating factor acetylhydrolase, generates two bioactive products during the oxidation of low-density lipoprotein: use of a novel inhibitor. Biochem J 338(Pt 2):479-487.
23. McConnell JP, Hoefner DM. 2006. Lipoprotein-associated phospholipase A2. Clin Lab Med 26(3):679-697.
24. Peters A, Dockery DW, Muller JE, Mittleman MA. 2001. Increased particulate air pollution and the triggering of myocardial infarction. Circulation 103(23):2810-2815.
25. Peters A, Schneider A, Greven S, Bellander T, Forastiere F, Ibald-Mulli A, et al. 2007. Air pollution and inflammatory response in myocardial infarction survivors: gene-environment interactions in a high-risk group. Inhal Toxicol 19(suppl 1):161-175.
26. Peters A, von Klot S, Heier M, Trentinaglia I, Hormann A, Wichmann HE, et al. 2004. Exposure to traffic and the onset of myocardial infarction. N Engl J Med 351(17):1721-1730.
27. Puustinen A, Hämeri K, Pekkanen J, Kulmala M, de Hartog J, Meliefste K, et al. 2007. Spatial variation of particle number and mass over four European cities. Atmos Environ 41(31):6622-6636.
28. Rückerl R, Greven S, Ljungman P, Aalto P, Antoniades C, Bellander T, et al. 2007. Air Pollution and inflammation (interleukin-6, C-reactive protein, fibrinogen) in myocardial infarction survivors. Environ Health Perspect 115(7):1072-1080.
29. Schwartz J. 1997. Air pollution and hospital admissions for cardiovascular disease in Tucson. Epidemiology 8(4):371-377.
30. Zalewski A, Macphee C. 2005. Role of lipoprotein-associated phospholipase A2 in atherosclerosis: biology, epidemiology, and possible therapeutic target. Arterioscler Thromb Vasc Biol 25(5):923-931.